Ornithine

Summary

Ornithine is a conditionally essential amino acid that occurs naturally in the body and in various organisms. It is a component of bacterial membrane lipids, a substrate in the urea cycle, and is formulated together with L‑aspartate (LOLA) for medical use. Research has explored its role in liver disease, imaging agents, and as a nutritional supplement in wound care.

Mechanism of Action

In the urea cycle, ornithine accepts carbamoyl groups, enabling conversion of toxic ammonia into urea for excretion; this underlies the ammonia‑lowering effect of L‑ornithine‑L‑aspartate (LOLA). In bacterial membranes, ornithine is incorporated into specialized lipids that affect membrane structure. Radiolabeled ornithine‑containing peptides bind integrin αvβ3 receptors, allowing tumor imaging. When supplied as ornithine‑α‑ketoglutarate, it may provide nitrogen and carbon precursors that support tissue repair, although the exact metabolic pathways are not fully defined in humans.

What the Research Shows

A 2022 double‑blind, placebo‑controlled trial in 140 cirrhotic patients with severe hepatic encephalopathy (HE) showed that intravenous LOLA (30 g/24 h for 5 days) added to standard lactulose‑rifaximin therapy improved HE grade in 92.5% of patients versus 66% with standard therapy alone, shortened recovery time, and reduced 28‑day mortality (16.4% vs 41.8%). Bacterial studies describe ornithine‑containing lipids as part of diverse membrane compositions. A radiolabeled ornithine‑rich peptide demonstrated tumor accumulation in mouse imaging models. A Cochrane review identified very low‑certainty evidence that ornithine‑α‑ketoglutarate supplementation might influence pressure‑ulcer healing, but data were sparse.

Reported Benefits

Clinical evidence supports LOLA for acute treatment of overt hepatic encephalopathy, with higher rates of neurological improvement, faster recovery, and lower short‑term mortality when combined with standard therapies. Preliminary animal imaging studies suggest ornithine‑based radioligands can target integrin‑expressing tumors. Very limited data hint at possible benefits of ornithine‑α‑ketoglutarate in wound healing, though the evidence is low certainty.

Limitations of the Evidence

The HE benefit rests on a single randomized trial; broader population data and long‑term outcomes are lacking. Imaging findings are confined to pre‑clinical mouse models, limiting direct clinical relevance. Nutritional studies on pressure‑ulcer outcomes involve few participants and provide very low‑certainty evidence, preventing firm conclusions. No large‑scale safety or dose‑finding studies are reported for oral or subcutaneous formulations.

Safety Considerations

The HE trial did not report serious adverse events attributable to LOLA, and no major safety concerns were highlighted in the abstract. However, comprehensive safety data, including potential gastrointestinal, metabolic, or allergic reactions, are not provided. Caution is advised when using high‑dose intravenous formulations, especially in patients with renal impairment or electrolyte disturbances, until further safety studies are available.

How It Is Administered

Ornithine can be delivered intravenously, orally, or subcutaneously. In the HE study, it was administered as a continuous intravenous infusion of 30 g over 24 hours for five consecutive days, combined with lactulose and rifaximin. Oral and subcutaneous preparations are available for research and nutritional purposes, but specific dosing regimens are not detailed in the cited literature.

Routes of Administration

Goals & Uses

• Hepatic encephalopathy managementHepatologyModerate
• Wound healing and tissue repairSurgery / RecoveryLow
• Ammonia detoxificationMetabolic SupportModerate
• Growth hormone stimulationEndocrine / HormonalLow
• Exercise performance and fatigue reductionSports / PerformanceLow

Contraindications

• Known hypersensitivity to ornithine or formulation componentsAllergyHigh
• Severe renal impairmentOrganModerateKidney function concerns
• Pregnancy and lactationReproductiveModerate

Adverse Effects

• HeadacheNeurologicUncommonPain in the head or upper neck
• Gastrointestinal discomfortGastrointestinalCommon
• Nausea and vomitingGastrointestinalCommon
• Electrolyte imbalanceMetabolicUncommonAbnormal blood electrolyte levels

Drug Interactions

• RifaximinLow
• LactuloseLow
• Growth hormone / secretagoguesLow

Population Constraints

• Pediatric populationsAgeRelative
• Chronic kidney diseaseRenalRelative
• Patients with urea cycle disordersMetabolic DisorderRelative

Regulatory Status

• European UnionApprovedApproved: Hepatic encephalopathy (LOLA form)LOLA is approved in several EU member states for hepatic encephalopathy; regulatory status varies by country.
• United StatesUnapprovedAvailable OTC as a dietary supplement (DSHEA); not FDA-approved as a drug. LOLA not FDA-approved.
• United KingdomUnknownL-Ornithine available as a food supplement; LOLA prescription status varies; consult MHRA guidance.

L-Ornithine is sold as an over-the-counter dietary supplement in the US and many countries. L-Ornithine L-Aspartate (LOLA) is approved as a prescription drug in some European and Asian countries for hepatic encephalopathy but is not FDA-approved. Not classified as a peptide per se, but frequently grouped with amino acid therapeutics.

Evidence & Sources

• Bacterial membrane lipids: diversity in structures and pathways
  Journal ArticleModerateSohlenkamp C, Geiger O2016-01-01T00:00:00.000000Z
• Urea Cycle Disorders Overview
  Journal ArticleModerateAdam MP, et al.1993-01-01T00:00:00.000000Z
• L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
  Journal ArticleModerateJain A, et al.2022-01-01T00:00:00.000000Z
• [(99m)Tc-Gly-Gly-Cys]-Ornithine-ornithine-ornithine-cyclo(Arg-Gly-Asp-d-Phe-Lys)
  Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
• Nutritional interventions for preventing and treating pressure ulcers
  Journal ArticleHighLanger G, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions